moguisteine nonnarcotic peripherally acting small doubleblind randomized controlled trial mg moguisteine suspension taken times daily significantly reduced frequency coughing patients copd compared also studied small trials comparison similar efficacy approved use united discovered searching expectorants thiazolidine class compounds cough suppressant effect accidentally found moguisteine selected effective safest representative mechanism action may activation atpsensitive potassium httpsenwikipediaorgwikimoguisteine